ClinicalTrials.gg
CompletedNCT04257929Updated May 12, 2026Results posted

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

A Phase 2 interventional study of Pitolisant oral tablets and Placebo oral tablet in Prader-Willi Syndrome, sponsored by Harmony Biosciences Management, Inc.. Completed at 13 sites in United States. Open to participants aged 6 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-12.

Sponsored by Harmony Biosciences Management, Inc. (part of Harmony Biosciences Holdings, Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
65
Allocation
Randomized
Ages
6 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
17th of 58
65 · median 23
Started
2020
with 2 others
Phase 2
17 of 69
1 open now
Registered
43rd of 69
by date
Lead sponsor
3 of 69
Harmony Biosciences Management, Inc.

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 17th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2020, is one of 17 in phase 2, and was the 43rd registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 6 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the safety and efficacy of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with Prader Willi syndrome (PWS) ages 6 to 65 years.

Read the detailed description

The study will consist of a Screening Period, an 11-week Double-Blind Treatment Phase (including a 3-week Titration Period and an 8-week Stable Dose Period), and an optional Open Label Extension (OLE) Phase. The OLE Phase will be multi-year in duration and will continue until the Sponsor elects to terminate the study.

Approximately 60 patients ages 6 to 65 years who meet all eligibility criteria will be randomized at the Baseline Visit in a 1:1:1 ratio to lower dose pitolisant, higher dose pitolisant, or matching placebo. In the Double-Blind Treatment Phase, patients will be titrated to their randomized stable dose of study drug during the 3-week Titration Period.

After completion of the 3-week Titration Period, patients will continue to take study drug at their randomized stable dose once daily in the morning upon wakening for an additional 8 weeks of blinded treatment (Stable Dose Period). The duration of the Double-Blind Treatment Phase will be 11 weeks.

Following the 11-week Double-Blind Treatment Phase, eligible patients will be given the opportunity to participate in an optional OLE Phase. During the OLE Phase, all eligible patients will receive treatment with open-label pitolisant and will undergo titration during a 3-week Titration Period to a maximum target dose as specified in the protocol. At the end of the 3-week Titration Period, patients will continue to take their target dose of pitolisant once daily in the morning upon wakening until the end of the study.

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

Keywords

  • PWS
04

Who can participate

Ages eligible
6 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is able to provide voluntary, written (patient or parent[s]/legal guardian[s]) and, where applicable, voluntary, written assent (patient, as appropriate).
  2. Has a diagnosis of PWS confirmed by genetic testing and/or patient medical records. Genetic testing will be provided by the Sponsor, if not confirmed based on the review of the patient's medical records.
  3. Male or female patients ages 6 to 65 years at the time of enrollment.
  4. Demonstrates adequate sleep duration via patient sleep diary during Screening, defined as at least 8 hours of sleep per night for patients ages 6 to \<12 years, at least 7 hours for patients ages 12 to \<18 years, or at least 6 hours for patients ages ≥18 years, based on the mean number of hours from up to 14 nights (at least 7 nights must be recorded for evaluation).
  5. Has EDS as determined by Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) (parent/caregiver version) score of ≥12.
  6. If taking hormone treatments (including growth hormone, testosterone, and estrogen supplements) and/or allowed chronic concomitant medication or supplements, patient must be on a stable dose of these medications for 3 months prior to randomization and for the duration of the Double-Blind Treatment Phase of the study; a 10% variability in hormone dose is allowed.
  7. If taking a wake-promoting treatment that could affect EDS (including stimulants, modafinil, and armodafinil), must be on a stable dose for at least 28 days prior to Screening and remain on a stable dose during the Double-Blind Treatment Phase of the study (dose adjustments will be permitted in the OLE Phase) or agree to wash out of treatment for 5 half-lives or 14 days, whichever is longer.
  8. If taking a chronically administered sedating medication for management of behavioral manifestations (e.g., hypnotics, benzodiazepines, antipsychotics, alpha agonists, anticholinergics, and antidepressants) must be on a stable dose for at least 28 days prior to Screening and remain on a stable dose during the Double-Blind Treatment Phase of the study (dose adjustments will be permitted in the OLE Phase) or agree to wash out of treatment for 5 half-lives or 14 days, whichever is longer.
  9. If using cannabidiol and/or tetrahydrocannabinol, patient must be on a stable dose for 28 days prior to randomization and agree to continue the stable dose for the duration of the Double-Blind Treatment Phase of the study (dose adjustments will be permitted in the OLE Phase).
  10. If taking oxytocin or carbetocin, patient must be on a stable dose during the 28 days prior to randomization and agree to continue the stable dose for the duration of the Double-Blind Treatment Phase of the study (dose adjustments will be permitted in the OLE Phase) or agree to wash out of treatment for 5 half-lives or 14 days, whichever is longer.
  11. A patient who is a female of (FCBP) must have a negative serum pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit and agree to remain abstinent or use an effective method of nonhormonal to prevent pregnancy for the duration of the study and for 21 days after final dose of study drug.
  12. Has a consistent caregiver (preferably the same person throughout the Double-Blind Treatment Phase of the study) who is willing and able to complete the required assessments.
  13. In the opinion of the Investigator, patient/parent(s)/legal guardian(s) is capable of understanding and complying with the requirements of the protocol and administration of oral study drug.

Exclusion criteria

Exclusion Criteria:

  1. Has a diagnosis of another genetic or chromosomal disorder distinct from PWS.
  2. Has untreated obstructive sleep apnea (OSA) or is at high risk for OSA based on medical history and clinical assessment; or, has another relevant underlying sleep disorder that in the opinion of the Investigator is the primary contributing factor to the patient's EDS.
  3. Consistently consumes >600 mg of caffeine per day and is unable/unwilling to reduce caffeine intake to \<600 mg per day for the duration of the Double-Blind Treatment Phase of the study; caffeine intake should remain consistent during Screening and throughout the Double-Blind Treatment Phase of the study.
  4. Does not agree to discontinue any prohibited medication or substance listed in the protocol.
  5. Participation in an interventional research study involving another medication or device in the 28 days prior to enrollment and for the duration of the Double-Blind Treatment Phase of the study, unless the Investigator consults with the Medical Monitor and obtains written approval for the patient to enroll; patients who complete a of an investigational medication of at least 5 half-lives or 14 days (whichever is longer) may be enrolled in the Double-Blind Treatment Phase of the study. Patients considering participation in another interventional research study in the OLE Phase must consult with the Investigator who will consult with the Medical Monitor.
  6. Has a primary psychiatric diagnosis with current active symptoms of psychosis or schizophrenia.
  7. Has a diagnosis of end-stage renal disease (estimated [eGFR] of \<15 mL/minute/1.73 m²) or severe hepatic impairment ( C).
  8. Has a diagnosis of moderate or severe renal impairment (eGFR ≥15 to ≤59 mL/minute/1.73 m²) or moderate hepatic impairment (Child-Pugh B) at Screening or during the Double-Blind Treatment Phase.
  9. Has abnormal laboratory values at Screening that are as determined by the Investigator.
  10. Has a known history of long syndrome or any significant history of a serious abnormality of the (ECG; e.g., recent myocardial infarction, clinically significant arrhythmia) or QT interval corrected for heart rate according to Fridericia's formula (QTcF) >442 ms for patients ages 0 to \<10 years and >439 ms for patients ages 10 to \<20 years, regardless of gender, and >450 ms for male patients and >470 ms for female patients ages 20 to 65 years. (ECG QTcF = QT/3√ RR) (Mason et al 2007).
  11. Has a family history of sudden/unexplained death, cardiac death, or death from a primary dysrhythmia potentially associated with QT prolongation in any family member.
  12. If receiving any new or initiating a change in allied health therapies or interventions for symptoms of PWS, must be on a stable course of therapy for at least 28 days prior to randomization.
  13. Has a current or recent (within one year) history of a substance use disorder or dependence disorder, including alcohol and caffeine use disorders as defined in the , 5th Edition (DSM-V).
  14. Has planned surgery during the Double-Blind Treatment Phase of the study; planned surgery is permitted during the OLE Phase.
  15. Is receiving a concomitant medication that is known to be a strong cytochrome P450 (CYP) 2D6 inhibitor, a strong inducer, or a centrally acting histamine 1 (H1) receptor antagonist; patients who complete a washout of these medications of at least 5 half-lives or 14 days (whichever is longer) can be enrolled in the Double-Blind Treatment Phase of the study. Use of strong CYP2D6 inhibitors and strong CYP3A4 inducers is allowed during the OLE Phase; however, adjustment of pitolisant dose is required. Although not prohibited during the OLE Phase of the study, use of H1 receptor antagonists should be avoided.
  16. Is receiving a medication known to prolong the QT interval.
  17. Has a significant risk of committing suicide based on history, routine psychiatric examination, Investigator's judgment, or an answer of "yes" on any question other than questions 1 to 3 on the Very Young Child/Cognitively Impaired-Lifetime Recent Columbia-Suicide Severity Rating Scale (C SSRS).
  18. Has a history of seizures that have recently (within 6 months) been treated with antiepileptic medications that are strong CYP3A4 inducers. Patients with a history of seizures must have a stable seizure history (e.g., frequency and severity) for at least 6 months prior to enrollment.
  19. Is currently breastfeeding or planning to breastfeed over the course of the study. Lactating women must agree not to breastfeed for the duration of the study (Double-Blind Treatment Phase and OLE Phase) and for 21 days after final dose of study drug.
  20. Based on the judgment of the Investigator, patient is unsuitable for the study for any reason, including but not limited to unstable or uncontrolled medical conditions (including psychiatric and neurological conditions) or a medical condition that might interfere with the conduct of the study, confound interpretation of study results, pose a health risk to the patient, or compromise the integrity of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
65 participants (actual)

Study arms

  • Active comparator
    Double-Blind Treatment Phase Lower Dose Pitolisant

    Pediatric patients (6 to less than 12 years of age): Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 8.9 mg pitolisant administered once daily in the morning. Adolescent patients (12 to less than 18 years of age): Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 13.35 mg pitolisant administered once daily in the morning. Adult patients (18 to 65 years of age): Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning.

    Drug: Pitolisant oral tablets

  • Active comparator
    Double-Blind Treatment Phase Higher Dose Pitolisant

    Pediatric patients (6 to less than 12 years of age): Week 1: 4.45 mg pitolisant administered once daily in the morning; Week 2: 8.9 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 17.8 mg pitolisant administered once daily in the morning. Adolescent patients (12 to less than 18 years of age): Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 26.7 mg pitolisant administered once daily in the morning. Adult patients (18 to 65 years of age): Week 1: 8.9 mg pitolisant administered once daily in the morning; Week 2: 17.8 mg pitolisant administered once daily in the morning; Weeks 3 through 11: 35.6 mg pitolisant administered once daily in the morning.

    Drug: Pitolisant oral tablets

  • Placebo comparator
    Double-Blind Treatment Phase Placebo

    Pediatric patients (6 to less than 12 years of age): Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets Adolescent patients (12 to less than 18 years of age): Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets Adult patients (18 to 65 years of age): Week 1: Matching placebo tablets; Week 2: Matching placebo tablets; Weeks 3 through 11: Matching placebo tablets

    Drug: Placebo oral tablet

  • Other
    Open-Label Pitolisant

    Age-based dosing (prior to implementation of amendment 6) or weight-based dosing (after implementation of amendment 6)

    Drug: Pitolisant oral tablets

Interventions

06

What researchers measure

Primary outcomes

  1. Excessive Daytime Sleepiness

    Change in Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) (parent/caregiver version) score from Baseline to Week 11 for pitolisant compared with placebo. The score of the ESS-CHAD ranges from 0 to 24. A decrease in score represents an improvement in excessive daytime sleepiness.

    Time frame: Baseline to Week 11

Secondary outcomes

  1. Excessive Daytime Sleepiness

    Change in Caregiver Global Impression of Severity for Excessive Daytime Sleepiness. The Caregiver Global Impression of Severity for Excessive Daytime Sleepiness is a five-item scale that ranges from "not at all" to "very high likelihood." An assessment of being less likely to fall asleep represents an improvement in the caregiver's overall impression of the patient's excessive daytime sleepiness.

    Time frame: Baseline to Week 11

  2. Clinical Symptoms

    Change in Clinical Global Impression of Severity of Overall Clinical Status. The Clinical Global Impression of Severity of Overall Clinical Status is a four-item scale that ranges from "normal" to "severely symptomatic." An assessment of less severe symptoms represents an improvement in the clinician's perception of the overall clinical status related to PWS.

    Time frame: Baseline to Week 11

  3. Behavior

    Change in Aberrant Behavior Checklist, Second Edition. The Aberrant Behavior Checklist-Community, Second Edition, rates 58 specific symptoms on a four-item scale ranging from "not at all a problem" to "the problem is severe in degree." A decrease in score represents an improvement in the caregiver's impression in the patient's problematic behavior.

    Time frame: Baseline to Week 11

  4. Behavioral and Cognitive Rigidity

    Change in Montefiore-Einstein Rigidity Scale - Prader-Willi Syndrome (MERS-R-PWS). The MERS-R-PWS is a clinician-rated, semi-structured interview conducted with both the patient with PWS and caregiver present. The MERS-R-PWS measures three domains of rigid behavior - behavior, cognitive, and protest. Within each domain, four items are rated on a scale ranging from 0 to 4. A decrease in score represents an improvement in rigid behavior.

    Time frame: Baseline to Week 11

  5. Psychomotor Function

    Change in Cogstate Detection Test. The Cogstate Detection Test is a computerized test. Accuracy with a faster speed represents an improvement in psychomotor test performance.

    Time frame: Baseline to Week 11

  6. Attention

    Change in Cogstate Identification Test. The Cogstate Identification Test is a computerized test. Accuracy with a faster speed represents an improvement in attention test performance.

    Time frame: Baseline to Week 11

  7. Working Memory

    Change in Cogstate One Back Test. The Cogstate One Back Test is a computerized test. Accuracy with a faster speed represents a better working memory test performance.

    Time frame: Baseline to Week 11

  8. Caregiver Burden

    Change in 22-Item Zarit Burden Interview. The Zarit Burden Interview is a self-reported questionnaire in which caregivers are asked to rate their experience on a five-item scale (0 = "never" and 4 = "nearly always") for 22 questions related to caregiver health and psychological well-being, finances, impact on social life, and relationship with the patient with PWS. A decrease in score represents an improvement in the caregiver's perceived burden.

    Time frame: Baseline to Week 11

07

Results

Posted Oct 22, 2025

Participant flow

Participant flow — Overall Study
MilestoneDouble-Blind Treatment Phase Lower Dose PitolisantDouble-Blind Treatment Phase Higher Dose PitolisantDouble-Blind Treatment Phase Placebo
Started202223
Completed182120
Not completed213
Withdrew: Adverse event101
Withdrew: Withdrawal by subject100
Withdrew: Covid-19011
Withdrew: Lost to follow-up001

Outcome measures

PrimaryExcessive Daytime Sleepiness

Change in Epworth Sleepiness Scale for Children and Adolescents (ESS-CHAD) (parent/caregiver version) score from Baseline to Week 11 for pitolisant compared with placebo. The score of the ESS-CHAD ranges from 0 to 24. A decrease in score represents an improvement in excessive daytime sleepiness.

Time frame:
Baseline to Week 11
Reported as:
Least squares mean · score on a scale
Excessive Daytime Sleepiness
score on a scaleDouble-Blind Treatment Phase Lower Dose PitolisantDouble-Blind Treatment Phase Higher Dose PitolisantDouble-Blind Treatment Phase Placebo
Excessive Daytime Sleepiness-3.5 ± 1.14-5.0 ± 1.07-3.9 ± 1.08
SecondaryExcessive Daytime Sleepiness

Change in Caregiver Global Impression of Severity for Excessive Daytime Sleepiness. The Caregiver Global Impression of Severity for Excessive Daytime Sleepiness is a five-item scale that ranges from "not at all" to "very high likelihood." An assessment of being less likely to fall asleep represents an improvement in the caregiver's overall impression of the patient's excessive daytime sleepiness.

Time frame:
Baseline to Week 11

Results for this outcome have not been posted.

SecondaryClinical Symptoms

Change in Clinical Global Impression of Severity of Overall Clinical Status. The Clinical Global Impression of Severity of Overall Clinical Status is a four-item scale that ranges from "normal" to "severely symptomatic." An assessment of less severe symptoms represents an improvement in the clinician's perception of the overall clinical status related to PWS.

Time frame:
Baseline to Week 11

Results for this outcome have not been posted.

SecondaryBehavior

Change in Aberrant Behavior Checklist, Second Edition. The Aberrant Behavior Checklist-Community, Second Edition, rates 58 specific symptoms on a four-item scale ranging from "not at all a problem" to "the problem is severe in degree." A decrease in score represents an improvement in the caregiver's impression in the patient's problematic behavior.

Time frame:
Baseline to Week 11

Results for this outcome have not been posted.

SecondaryBehavioral and Cognitive Rigidity

Change in Montefiore-Einstein Rigidity Scale - Prader-Willi Syndrome (MERS-R-PWS). The MERS-R-PWS is a clinician-rated, semi-structured interview conducted with both the patient with PWS and caregiver present. The MERS-R-PWS measures three domains of rigid behavior - behavior, cognitive, and protest. Within each domain, four items are rated on a scale ranging from 0 to 4. A decrease in score represents an improvement in rigid behavior.

Time frame:
Baseline to Week 11

Results for this outcome have not been posted.

SecondaryPsychomotor Function

Change in Cogstate Detection Test. The Cogstate Detection Test is a computerized test. Accuracy with a faster speed represents an improvement in psychomotor test performance.

Time frame:
Baseline to Week 11

Results for this outcome have not been posted.

SecondaryAttention

Change in Cogstate Identification Test. The Cogstate Identification Test is a computerized test. Accuracy with a faster speed represents an improvement in attention test performance.

Time frame:
Baseline to Week 11

Results for this outcome have not been posted.

SecondaryWorking Memory

Change in Cogstate One Back Test. The Cogstate One Back Test is a computerized test. Accuracy with a faster speed represents a better working memory test performance.

Time frame:
Baseline to Week 11

Results for this outcome have not been posted.

SecondaryCaregiver Burden

Change in 22-Item Zarit Burden Interview. The Zarit Burden Interview is a self-reported questionnaire in which caregivers are asked to rate their experience on a five-item scale (0 = "never" and 4 = "nearly always") for 22 questions related to caregiver health and psychological well-being, finances, impact on social life, and relationship with the patient with PWS. A decrease in score represents an improvement in the caregiver's perceived burden.

Time frame:
Baseline to Week 11

Results for this outcome have not been posted.

Adverse events

Collected over Data are presented for adverse events occurring after first dose of study drug and up to 30 days after the date of last dose of study drug, for a total of up to 15 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double-Blind Treatment Phase Lower Dose Pitolisant0/20 (0%)0/20 (0%)13/20 (65%)
Double-Blind Treatment Phase Higher Dose Pitolisant0/22 (0%)0/22 (0%)8/22 (36.4%)
Double-Blind Treatment Phase Placebo0/23 (0%)1/23 (4.3%)9/23 (39.1%)
Most frequent serious events
Most frequent serious events
EventDouble-Blind Treatment Phase Lower Dose PitolisantDouble-Blind Treatment Phase Higher Dose PitolisantDouble-Blind Treatment Phase Placebo
Deep vein thrombosisVascular disorders0/200/221/23
Most frequent other events
Most frequent other events
EventDouble-Blind Treatment Phase Lower Dose PitolisantDouble-Blind Treatment Phase Higher Dose PitolisantDouble-Blind Treatment Phase Placebo
AnxietyPsychiatric disorders4/201/222/23
IrritabilityPsychiatric disorders4/201/221/23
HeadacheNervous system disorders3/202/222/23
COVID-19Infections and infestations0/203/222/23
Sleep disorderPsychiatric disorders2/200/220/23
NasopharyngitisInfections and infestations2/202/221/23
Abdominal pain upperGastrointestinal disorders2/200/220/23
HyperphagiaMetabolism and nutrition disorders2/201/222/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double-Blind Treatment Phase Lower Dose PitolisantDouble-Blind Treatment Phase Higher Dose PitolisantDouble-Blind Treatment Phase PlaceboTotal
Mean12.1 ± 5.4413.1 ± 6.7011.9 ± 4.3112.4 ± 5.50
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Treatment Phase Lower Dose PitolisantDouble-Blind Treatment Phase Higher Dose PitolisantDouble-Blind Treatment Phase PlaceboTotal
Female1112932
Male9101433
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double-Blind Treatment Phase Lower Dose PitolisantDouble-Blind Treatment Phase Higher Dose PitolisantDouble-Blind Treatment Phase PlaceboTotal
Hispanic or Latino0224
Not Hispanic or Latino20202161
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Double-Blind Treatment Phase Lower Dose PitolisantDouble-Blind Treatment Phase Higher Dose PitolisantDouble-Blind Treatment Phase PlaceboTotal
United States20222365
08

Study locations

13 sites
  • Rady Children's Hospital - San Diego
    San Diego, California 92123, United States
  • Sleep Medicine Specialists of California
    San Ramon, California 94583, United States
  • Santa Monica Clinical Trials
    Santa Monica, California 90404, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Nemours Alfred I duPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • University of Florida College of Medicine
    Gainesville, Florida 32608, United States
  • Ann and Robert H Lurie Children's Hospital
    Chicago, Illinois 60611, United States
  • Johns Hopkins School of Medicine
    Baltimore, Maryland 21205, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68114, United States
  • CTI
    Cincinnati, Ohio 45212, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37203, United States
  • Texas Children's Hospital/Baylor College of Medicine
    Houston, Texas 77030, United States
  • Road Runner Research
    San Antonio, Texas 78249, United States
09

References and documents

Publications

  • Revana A, Bhattacharjee R, Miller JL, Chidekel A, Khanna P, Ratnam S, Runyan G, Bauer E, Davis Rapchak K, Seiden D, Budur K, Dayno JM. A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome. J Clin Sleep Med. 2025 Nov 1;21(11):1893-1902. doi: 10.5664/jcsm.11800. PubMed 40605372 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2020 to primary completion in Aug 2022, 20 months.

Results were first posted in Oct 2025, 3 years 2 months after primary completion. A results delay was requested in Jul 2023.

Of 11 phase 2 interventional studies under Prader-Willi Syndrome, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 27. This study's 20 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 29, 2020
First posted
Feb 6, 2020
StartActual
Dec 9, 2020
Primary completionActual
Aug 17, 2022
CompletionActual
Jan 21, 2026
Results delay requested
Jul 5, 2023
Results first posted
Oct 22, 2025
Last update
May 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04257929
Responsible party
Sponsor
First posted
Feb 6, 2020
Start date
Dec 9, 2020
Primary completion
Aug 17, 2022
Completion
Jan 21, 2026
Results posted
Oct 22, 2025
Last update
May 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pitolisant

Start the discussion